/CMRA
CMRA Stock - Comera Life Sciences Holdings, Inc.
Healthcare|BiotechnologyOTC
$0.00+0.00%
+$0.00 (+0.00%) • Dec 19
60
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.20
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CMRA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.00 – $0.00
TARGET (TP)$0.00
STOP LOSS$0.00
RISK/REWARD1:-1.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-20.43
52W High$0.00
52W Low$0.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2022 | FY2021 | FY2020 |
|---|---|---|---|
| Revenue | $633,102 | $319,832 | $442,919 |
| Gross Profit | $422,712 | $158,824 | $338,512 |
| Gross Margin | 66.8% | 49.7% | 76.4% |
| Operating Income | $-11,970,015 | $-5,535,628 | $-2,127,520 |
| Net Income | $-18,004,098 | $-5,451,778 | $-2,125,487 |
| Net Margin | -2843.8% | -1704.6% | -479.9% |
| EPS | $-1.76 | $-0.29 | $-0.11 |
Company Overview
Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions. The company is advancing its primary product programs, CLS-001, a preclinical stage biobetter for Crohn's and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
CMRABeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.10
Q4 2023
EPS Surprise History
Q4 21
No data
Q1 22
No data
Q3 22
No data
Q4 22
No data
Q1 23
No data
Q2 23
No data
Q3 23
No data
Q4 23
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2023 | Nov 9, 2023 | — | $-0.10 | — | — |
Q3 2023 | Aug 10, 2023 | — | $-0.08 | — | — |
Q2 2023 | May 11, 2023 | — | $-0.13 | — | — |
Q1 2023 | Mar 16, 2023 | — | $-0.18 | — | — |
Q4 2022 | Nov 10, 2022 | — | $-0.20 | — | — |
Q3 2022 | Aug 10, 2022 | — | $-1.74 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.17 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.07 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.05 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.10 | — | — |
Latest News
Loading news...
Frequently Asked Questions about CMRA
What is CMRA's current stock price?
Comera Life Sciences Holdings, Inc. (CMRA) is currently trading at $0.00 per share. The stock has moved +0.00% today.
What is the analyst price target for CMRA?
No analyst price targets are currently available for this stock.
What sector is Comera Life Sciences Holdings, Inc. in?
Comera Life Sciences Holdings, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is CMRA's market cap?
Comera Life Sciences Holdings, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does CMRA pay dividends?
No, Comera Life Sciences Holdings, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANTH
Anthera Pharmaceuticals, Inc.
$0.00
Mkt Cap: $0.0B
COTQF
Cotinga Pharmaceuticals Inc.
$0.00
Mkt Cap: $0.0B
FPMI
FluoroPharma Medical, Inc.
$0.00
Mkt Cap: $0.0B
GBIM
GlobeImmune, Inc.
$0.00
Mkt Cap: $0.0B
NLVVF
New Leaf Ventures Inc
$0.00
Mkt Cap: $0.0B
NTII
Neurobiological Technologies, Inc.
$0.00
Mkt Cap: $0.0B
RBSH
Rebus Holdings, Inc.
$0.00
Mkt Cap: $0.0B
SNNAQ
Sienna Biopharmaceuticals, Inc.
$0.00
Mkt Cap: $0.0B
SYVC
Synovics Pharmaceuticals, Inc.
$0.00
Mkt Cap: $0.0B
TNGNQ
Tengion, Inc.
$0.00
Mkt Cap: $0.0B
Explore stocks similar to CMRA for comparison